ALFA Finder| Revenue growth | Standalone up 14% YoY; Consolidated down 8% YoY. |
|---|---|
| Margins | Standalone Gross Margins improved to 78% from 69%. |
| Demand visibility | Strong poultry demand; Animal health impacted by tender timing. |
| Management confidence | Confident in long-term growth despite short-term tender delays. |
Growth
Standalone revenue grew 14% YoY; Poultry Healthcare rose 48% due to higher institutional sales. Consolidated revenue fell 8% on Africa/Nepal weakness.
Outlook
Management focuses on expanding market penetration and strengthening biologicals portfolio across Poultry and Animal Healthcare divisions.
Risks
Animal Healthcare segment down 50% due to government tender delays. Profitability heavily dependent on one-time accounting gains.
Last quarter's promises, checked
Delivered
- Guided focus on bottom line → delivered Standalone PAT up 174% (= BEAT)
- Guided stronger execution in Poultry → delivered 41% Q4 segment growth (= BEAT)
- Targeted debt reduction → delivered debt reduced from INR 102cr to INR 70cr (= BEAT)
Partly delivered
- Targeted BSL-3 facility ramp-up → delivered ongoing optimization initiatives (= PARTIAL)
Missed
- Guided Animal Health recovery → delivered segment revenue down 50% (= MISS)
Earnings Call Transcript filed with NSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,341.30
- Market cap
- ₹1,992 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 14.0×Sector 43.8×
- Promoter holding
- 44.28%-9.45% QoQ
- FII holding
- 0.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Investor Presentation: Key Takeaways
Standalone revenue +28% Q2, +21% H1; PAT +131% Q2. EBITDA margin 35%, gross margin 78%. H1 consolidated PAT boosted by one-time Africa loan gain.
Hester Biosciences Q2 FY27 Results: Net Profit ₹20.6 Cr, Up 44.1% YoY
Hester Biosciences Ltd reported revenue from operations of ₹97.9 Cr (+37.9% YoY) and net profit of ₹20.6 Cr (+44.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.6 Cr · +44.1% YoY
Hester Biosciences Board Meeting Date
Hester Biosciences scheduled its Board of Directors meeting for 5 November 2026 to review unaudited H1 FY27 results. No decisions or figures are reported yet.
Hester Biosciences Management Change
Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.
Hester Biosciences Other Announcement
Hester Biosciences reported shareholding data for the quarter ending September 2026. Two promoters were reclassified as public shareholders, reducing the promoter holding.
Hester Biosciences Capacity Expansion: ₹1.05 Cr Investment
Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.
- Value
- ₹1.05 Cr
- Execution
- six months